CareDx Receives Final Medicare Coverage Decision for AlloSure Heart
AlloSure Heart is a donor-derived cell-free DNA (dd-cfDNA) test which can identify underlying cell injury leading to organ rejection. Medicare reimbursement for AlloSure Heart followed a rigorous technical assessment by the MolDx program and further highlights the value of dd-cfDNA testing for transplant patient management. AlloSure Heart was validated in a multicenter prospective study published in the
The final coverage decision also paves the way for HeartCare, the combination of AlloSure Heart and AlloMap Heart, to be made available to providers and patients. The combined use of AlloSure Heart dd-cfDNA and AlloMap Heart gene expression profiling provides a multi-modality and noninvasive solution for managing the care of transplant patients.
“HeartCare has been instrumental in managing our patients. Especially in the COVID pandemic where access to in-person biopsies is more limited, a non-invasive solution for our patients is game-changing for home management of heart transplant recipients,” said
“The Medicare coverage determination expands access to our non-invasive solutions, optimizes patient care, and helps fulfill the healthcare team objective of one organ for life,” said
About
CONTACTS:
Chief Marketing Officer
415-287-2393
sking@caredx.com
Investor Relations
347-620-7010
investor@caredx.com
Source: CareDx, Inc.